Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function

Group 1: Subjects with mild renal impairment (eGFR ≥ 60 and \< 90 mL/min)

Group 2: Subjects with moderate renal impairment (eGFR ≥ 30 and \< 60 mL/min)

Group 3: Subjects with severe renal impairment (eGFR \< 30 mL/min), or kidney failure and not receiving dialysis

Group 4: Matched healthy subjects with normal renal function (eGFR ≥ 90 mL/min)